After a long road to approval for its nontherapeutic radiopharmaceutical Amyvid florbetapir F 18 injection the issue Lilly has been grappling with over the past year – Medicare reimbursement…
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!INDIANAPOLIS, May 14, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that…
(Reuters) - John Lechleiter, the longtime chief executive of Eli Lilly and Co, is recovering from successful surgery to repair a dilated aorta, the U.S. drugmaker said on Tuesday.
May 14 (Reuters) - John Lechleiter, the longtime chief executive of Eli Lilly and Co, is recovering from successful surgery to repair a dilated aorta, the U.S. drugmaker said on Tuesday.
